MX2024012302A - Métodos para tratar leucocitosis, disfunción endotelial y carditis usando complejos basados en proteína de unión a lípidos - Google Patents

Métodos para tratar leucocitosis, disfunción endotelial y carditis usando complejos basados en proteína de unión a lípidos

Info

Publication number
MX2024012302A
MX2024012302A MX2024012302A MX2024012302A MX2024012302A MX 2024012302 A MX2024012302 A MX 2024012302A MX 2024012302 A MX2024012302 A MX 2024012302A MX 2024012302 A MX2024012302 A MX 2024012302A MX 2024012302 A MX2024012302 A MX 2024012302A
Authority
MX
Mexico
Prior art keywords
carditis
methods
binding protein
endothelial dysfunction
lipid binding
Prior art date
Application number
MX2024012302A
Other languages
English (en)
Spanish (es)
Inventor
Cyrille Tupin
Constance Peyrottes
Ronald Barbaras
Original Assignee
Abionyx Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abionyx Pharma Sa filed Critical Abionyx Pharma Sa
Publication of MX2024012302A publication Critical patent/MX2024012302A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MX2024012302A 2022-04-06 2024-10-03 Métodos para tratar leucocitosis, disfunción endotelial y carditis usando complejos basados en proteína de unión a lípidos MX2024012302A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263328210P 2022-04-06 2022-04-06
PCT/IB2023/000183 WO2023194798A1 (en) 2022-04-06 2023-04-06 Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes

Publications (1)

Publication Number Publication Date
MX2024012302A true MX2024012302A (es) 2025-02-10

Family

ID=86732365

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024012302A MX2024012302A (es) 2022-04-06 2024-10-03 Métodos para tratar leucocitosis, disfunción endotelial y carditis usando complejos basados en proteína de unión a lípidos

Country Status (10)

Country Link
US (1) US20250255931A1 (cg-RX-API-DMAC7.html)
EP (1) EP4504233A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025512987A (cg-RX-API-DMAC7.html)
KR (1) KR20240171131A (cg-RX-API-DMAC7.html)
CN (1) CN119317440A (cg-RX-API-DMAC7.html)
AU (1) AU2023251245A1 (cg-RX-API-DMAC7.html)
CA (1) CA3247588A1 (cg-RX-API-DMAC7.html)
IL (1) IL316100A (cg-RX-API-DMAC7.html)
MX (1) MX2024012302A (cg-RX-API-DMAC7.html)
WO (1) WO2023194798A1 (cg-RX-API-DMAC7.html)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128318A (en) 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
GB8712540D0 (en) 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
US5220043A (en) 1991-03-21 1993-06-15 Ohio University Synthesis of D-erythro-sphingomyelins
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
EP0751961A1 (en) 1994-03-22 1997-01-08 Research Corporation Technologies, Inc. Eating suppressant peptides
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
DK1290013T3 (da) 2000-04-21 2006-06-26 Amgen Inc Apo-A1/All-peptidderivater
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
WO2002038609A2 (en) 2000-11-10 2002-05-16 Proteopharma Aps Apolipoprotein conjugates
US7217785B2 (en) 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
ES2304452T3 (es) 2001-08-20 2008-10-16 Csl Behring Ag Una hdl para el tratamiento de un ictus y de otras condiciones isquemicas.
US7223726B2 (en) 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
MXPA04011312A (es) 2002-05-17 2005-02-14 Esperion Therapeutics Inc Metodo para el tratamiento de desordenes dislipidemicos.
US6953840B2 (en) 2002-07-30 2005-10-11 Esperion Therapeutics, Inc. Methods of using non-human animal Apolipoprotein A-I protein
WO2004073684A2 (en) 2003-02-14 2004-09-02 Children's Hospital & Research Center At Oakland Lipophilic drug delivery vehicle and methods of use thereof
JP5048486B2 (ja) 2004-07-16 2012-10-17 トラスティーズ オブ タフツ カレッジ アポリポタンパク質a1の模倣物とその使用
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
BRPI0614966A2 (pt) 2005-08-26 2016-09-13 Cerenis Therapeutics Holding S A vetor de expressão, bactéria de ácido lático, apolipoproteína isenta de endotoxina, e, método de produção de uma apolipoproteína isenta de endotoxina
US8541236B2 (en) 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
WO2008104890A2 (en) 2007-02-28 2008-09-04 Cerenis Therapeutics Holding Sa Compositions and methods for producing apolipoprotein
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
ES2601830T3 (es) 2007-10-23 2017-02-16 The Cleveland Clinic Foundation Apolipoproteína A-1 resistente a oxidantes y péptidos miméticos
MX2011008599A (es) 2009-02-16 2011-11-18 Cerenis Therapeutics Sa Peptidos mimeticos de la apolipoproteina a-i.
WO2011143362A1 (en) 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Dimeric oxidation-resistant apolipoprotein a1 variants
LT2673296T (lt) 2011-02-07 2019-02-25 Cerenis Therapeutics Holding Sa Lipoproteino kompleksai ir jų gamyba ir jų panaudojimai
SG11201506456VA (en) 2013-03-15 2015-09-29 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
RU2016144908A (ru) 2014-05-02 2018-06-05 Серени Терапеутикс Холдинг Са Маркеры hdl-терапии
KR20230004605A (ko) * 2020-04-16 2023-01-06 아비오닉스 파마 에스에이 지질 결합 단백질-기반 복합체를 사용하여 급성 상태를 치료하는 방법
AU2021254856A1 (en) * 2020-04-16 2022-11-10 Abionyx Pharma Sa CER-001 therapy for treating kidney disease

Also Published As

Publication number Publication date
CN119317440A (zh) 2025-01-14
EP4504233A1 (en) 2025-02-12
US20250255931A1 (en) 2025-08-14
CA3247588A1 (en) 2023-10-12
WO2023194798A1 (en) 2023-10-12
JP2025512987A (ja) 2025-04-22
KR20240171131A (ko) 2024-12-06
IL316100A (en) 2024-12-01
AU2023251245A1 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
AR126205A2 (es) Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
UA130357C2 (uk) Карбоксибензімідазольні сполуки, які модулюють glp-1r
PH12022550932A1 (en) Glp-1r modulating compounds
BR112022018949A2 (pt) Anticorpos monoclonais humanos para síndrome respiratória aguda grave coronavírus 2 (sars-cov-2)
PH12023552860A1 (en) Carboxy-benzimidazole glp-1r modulating compounds
ECSP21026021A (es) Moduladores de la expresión de pnpla3
CO2021013279A2 (es) Anticuerpos de cadena pesada que se unen al psma
DOP2020000020A (es) Anticuerpos anti-cd137
NZ767596A (en) Antibodies that bind cd39 and uses thereof
CO2021011034A2 (es) Métodos para tratar el mieloma múltiple
ECSP17073209A (es) Composiciones y métodos para el tratamiento de la anemia
CL2021003563A1 (es) Anticuerpos para la unión a psma
MX2020006963A (es) Composiciones y metodos para tratar anemia.
AR112015A1 (es) Composiciones sólidas para administración oral
CL2020002600A1 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
CL2020001851A1 (es) Moduladores de la expresión dnm2
PE20230091A1 (es) Conjugados terapeuticos
MX2022012906A (es) Terapia con cer-001 para tratar enfermedad renal.
CO2022006367A2 (es) Tratamiento génico para la enfermedad de alzheimer
AR117094A1 (es) Moduladores de expresión irf5
MX2019012029A (es) Metodo para tratar el cabello, kit y uso del kit.
EP4653465A3 (en) Methods of reversing ticagrelor activity
DE502006008168D1 (de) Filznadelverpackung
AR118721A1 (es) Métodos para tratar el cáncer renal con un anticuerpo anti-psma / cd3
MX2022006812A (es) Metodos para tratar epoc mediante la administracion de un antagonista de il-33.